On early September 2023, Eurovisco held its annual consensus meeting gathering Europeans osteoarthritis experts. This year’s aim was to determine the imaging and clinical criteria that influence the success rate of treatment of knee osteoarthritis by injection of an HA-based viscosupplement. Dr Thierry Conrozier masterfully chaired this meeting and Labrha Read more…
LABRHA is supporting Eurovisco by organizing its annual board since 2014. We are proud to be Eurovisco’s partner. Viscosupplementation for the treatment of osteoarthritis. The contribution of EUROVISCO group Thierry Conrozier 1 , Raghu Raman 2 , Xavier Chevalier 3 , Yves Henrotin 4 , Jordi Monfort 5 , Demirhan Read more…
LABRHA is supporting Eurovisco by organizing its annual board since 2014. We are proud to be Eurovisco’s partner. Abstract Objectives: Hyaluronic acid viscosupplementation is a commonly used intra-articular treatment for osteoarthritis (OA). Some recent preclinical and clinical trials have demonstrated a potential for its disease-modifying effects. The goal of this expert Read more…
LABRHA is supporting Eurovisco by organizing its annual board since 2014. We are proud to be Eurovisco’s partner. Abstract Objectives The 3 aims of the work were to identify population subgroups that can benefit the most from viscosupplementation (VS), to provide recommendations on injection techniques, and to discuss VS appropriateness Read more…
LABRHA is supporting Eurovisco by organizing its annual board since 2014. We are proud to be Eurovisco’s partner. Abstract Rationale Viscosupplementation (VS) with hyaluronic acid is widely used in the management of knee osteoarthritis. There is no clear recommendation on the decision-making to achieve VS. Design Based on extensive research Read more…